People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other, Construction
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. | — | Biotechnology | Series C | $91.0M | $1.3B | 2015 |
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $427.0M | 2019 |
| Dualitas Therapeutics, Inc. | — | Biotechnology | Series B | $32.6M | $150.4M | 2025 |
| Telarus Parent Holdings, Inc. | — | Other | Series B | $18.0M | $271.1M | 2020 |
| Variance Acrylic Finishes, LLC | — | Construction | Pre-Seed | $200K | $1.9M | 2009 |
Richard Murray at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Murray on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark McDade | 2 | 5 |
| Michael Ross | 1 | 18 |
| Peter Finn | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Thomas Hudson | 1 | 4 |
| Nikola Trbovic | 1 | 3 |
| Kim C. Drapkin | 1 | 3 |
| Cary G. Pfeffer | 1 | 3 |
| Chidozie Ugwumba | 1 | 3 |
| Philip Reilly | 1 | 2 |
| Neil Weir | 1 | 2 |
| Elizabeth G. Trehu | 1 | 2 |
| Kimberlee C. Drapkin | 1 | 2 |
| Jonathan Thon | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Greg Lazar | 1 | 1 |
| Anna L. Barry | 1 | 1 |
| Robert G. Tepper | 1 | 1 |
| Robin S Knight | 1 | 1 |
| Sam Rasty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.